Bas, O. Et Al. 2020. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma. Journal of Oncology Pharmacy Practice , vol.26, no.5 , 1230-1233.

Bas, O., Ozbek, A., Guven, D., Aktepe, O. H., KILIÇ, L., KERTMEN, N., ... ERMAN, M.(2020). Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma. Journal of Oncology Pharmacy Practice , vol.26, no.5, 1230-1233.

Bas, Onur Et Al. "Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma," Journal of Oncology Pharmacy Practice , vol.26, no.5, 1230-1233, 2020

Bas, Onur Et Al. "Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma." Journal of Oncology Pharmacy Practice , vol.26, no.5, pp.1230-1233, 2020

Bas, O. Et Al. (2020) . "Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma." Journal of Oncology Pharmacy Practice , vol.26, no.5, pp.1230-1233.

@article{article, author={Onur Bas Et Al. }, title={Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma}, journal={Journal of Oncology Pharmacy Practice}, year=2020, pages={1230-1233} }